Indeed, some alternative approaches for targeting FLT3-mutated AML have been focused on targeting downstream pathways (ERK1/2, CDK1, STAT5) that are activated by FLT3-ITD [11, 12, 21, 22]. The gene discussed is MAPK3; the disease is acute myeloid leukemia.